ZIM Laboratories Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, during a board meeting held on February 11, 2026. For the quarter ended December 31, 2025 (Q3 FY26), the company reported a total operating income of ₹1,087 million, representing a 12.8% year-on-year (YoY) increase from ₹963 million in Q3 FY25 and a 22.5% quarter-on-quarter (QoQ) growth from ₹887 million in Q2 FY26. Despite this revenue growth, the company faced significant pressure on its net profits, continuing a trend observed in previous periods where net profits fell substantially compared to the previous year. The company also approved a strategic investment of up to USD 15,000 to incorporate a wholly-owned subsidiary in Chile, targeting the LATAM region to further its global market penetration.

ZIM Laboratories Limited, based in Nagpur, India, is a research-driven pharmaceutical company established in 1989. The company specializes in developing, manufacturing, and marketing innovative drug delivery systems, particularly focusing on pre-formulation intermediates (PFI) and finished formulations. It is well-known for its proprietary technologies like “Zaydis,” a fast-dissolving oral dosage form, and its range of oral thin films (OTF). ZIM Laboratories maintains a strong global presence, exporting to over 20 countries across the Middle East, Asia, Africa, and Latin America, with nearly 79% of its total operating income derived from overseas markets as of 2025. The company is currently focused on patient-centric drug delivery solutions and is expanding its manufacturing capacity through organic growth initiatives.